| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 24 |
| 1 | PREDNISONE | 21 |
| 2 | METHYLPREDNISOLONE | 16 |
| 3 | MYCOPHENOLATE MOFETIL | 16 |
| 4 | RITUXIMAB | 16 |
| 5 | TACROLIMUS | 15 |
| 6 | DEXAMETHASONE | 14 |
| 7 | DEXAMETHASONE 1.5 MG | 14 |
| 8 | PREDNISOLONE | 14 |
| 9 | PREDNISOLONE ORAL | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | 1 | 0.0018 |
| 1 | XYLOMETAZOLINE HYDROCHLORIDE | 1 | 0.0018 |
| 2 | SORBITOL | 1 | 0.0017 |
| 3 | SILTUXIMAB | 1 | 0.0015 |
| 4 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | 1 | 0.0015 |
| 5 | RAMUCIRUMAB | 6 | 0.0009 |
| 6 | VORINOSTAT | 2 | 0.0009 |
| 7 | SODIUM FERRIC GLUCONATE COMPLEX | 2 | 0.0009 |
| 8 | CARMUSTINE | 4 | 0.0008 |
| 9 | ZOLBETUXIMAB | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 63 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 24 |
| 2 | Platinum-based Drug [EPC] | 22 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 21 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 19 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 16 |
| 6 | Alkylating Drug [EPC] | 15 |
| 7 | Proton Pump Inhibitor [EPC] | 14 |
| 8 | Kinase Inhibitor [EPC] | 11 |
| 9 | Microtubule Inhibitor [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 6 | 0.0009 |
| 2 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 3 | Histone Deacetylase Inhibitor [EPC] | 2 | 0.0005 |
| 4 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 5 | 0.0004 |
| 5 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 6 | Catechol-O-Methyltransferase Inhibitor [EPC] | 1 | 0.0002 |
| 7 | Asparagine-specific Enzyme [EPC] | 2 | 0.0001 |
| 8 | Parenteral Iron Replacement [EPC] | 2 | 0.0001 |
| 9 | Somatostatin Analog [EPC] | 1 | 0.0001 |